ALX Oncology Holdings (ALXO)
(Delayed Data from NSDQ)
$2.18 USD
+0.27 (14.14%)
Updated Oct 3, 2025 03:59 PM ET
After-Market: $2.17 -0.01 (-0.46%) 7:58 PM ET
3-Hold of 5 3
F Value B Growth D Momentum D VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
ALXO 2.18 +0.27(14.14%)
Will ALXO be a Portfolio Killer in October?
Zacks Investment Research is releasing its prediction for ALXO based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for ALXO
ALX Oncology Holdings (ALXO) Could Find a Support Soon, Here's Why You Should Buy the Stock Now
Is ALX Oncology Holdings (ALXO) Outperforming Other Medical Stocks This Year?
ALXO: What are Zacks experts saying now?
Zacks Private Portfolio Services
ALX Oncology Holdings (ALXO) Loses -27.11% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
Other News for ALXO
ALXO makes New 52 Week Closing High on October 3
Is ALXO gaining bullish strength? New 52 Week Closing High shows up after rocketing 6.08%
The technical outlook for ALXO is unchanged after it falls 1.09% on October 1
ALXO forms 180 Bullish Setup on September 30
Is ALXO building bearish momentum? Bearish Engulfing shows up after tumbling 6.42%